Page 3 - Patanjali Ayurved

Entire country is taken for a ride: SC contempt notice to Patanjali on ads

Misleading ads banned, Centre told to list out steps against false claims

Ramdev under fire: Stop Allopathy vs Ayurveda debate, misleading Ads, SC warns Patanjali

Not making false ad, ready for death sentence if found guilty: Patanjali

Baba Ramdev-led Patanjali Ayurved on Wednesday said it was not making any "false advertisements or propaganda" regarding its products, and said it would not object if the Supreme Court were to impose a fine or "even give us a death sentence" if found making misleading claims. A day after the apex court cautioned the company against making "false" and "misleading" claims in advertisements about its medicines as cure of several diseases, Patanjali Ayurved said it has "database with more than one crore people, with real world evidence, preclinical and clinical evidence". "Patanjali have made thousands of people free from several diseases like BP, sugar, thyroid, asthma, arthritis, obesity, liver and kidney failure, and cancer," the company asserted. The company further said, "We humbly respect the Supreme Court of India and if we make false advertisements or propaganda, we would not have any objections if honourable court imposes a fine of crores or even give us a death sentence." On

Patanjali Ayurved to sell 7% stake in its group firm Patanjali Foods

Baba Ramdev-led Patanjali Ayurved Ltd will sell up to 2.53 crore shares in its group firm Patanjali Foods Ltd on stock exchanges in a bid to increase public float to meet listing requirements. The shares of Patanjali Foods, which is into edible oil and other food products, will be offloaded through the Offer For Sale (OFS) route. The floor price has been fixed at Rs 1,000 per equity share for the offer, which will be open on July 13 and 14, according to a regulatory filing by Patanjali Foods on Wednesday. At the floor price, Patanjali Ayurved -- a promoter of Patanjali Foods -- will garner at least Rs 2,530 crore from the share sale. Shares of Patanjali Foods closed marginally higher at Rs 1,228.05 apiece at BSE on Wednesday and its market capitalisation stood at Rs 44,454.78 crore. "Seller (Patanjali Ayurved) proposes to sell up to 25,339,640 equity shares of face value of Rs 2 each of the company (representing 7 per cent of the total paid-up equity share capital of the ...

Five additional brands crossed Rs 100 cr in sales in FY23, says Dabur India

With reduced prices for most of its commodities, Dabur India expects to see expansion in gross margins in the current fiscal; the FMGC major has made an entry into the spices category

Patanjali Foods says not considering FPO to increase public shareholding

But other modes like OFS, QIP to raise public shareholding

Patanjali Foods Q3 profit rises 15% to Rs 269 crore on better sales

Patanjali Foods Ltd, which is mainly into edible oil business, has posted a 15 per cent growth in its net profit to Rs 269.18 crore for the December quarter on better sales. Its net profit stood at Rs 234.07 crore in the year-ago period, according to a regulatory filing. Total income rose by 26 per cent to Rs 7,963.75 crore during the quarter ended December 31, as compared to Rs 6,301.19 crore in the corresponding period of the previous year. During the April-December period of this fiscal, nine-month period ended December 31, 2022, net profit increased to Rs 622.73 crore from Rs 571.87 crore a year ago, said Patanjali Foods, which is part of Baba Ramdev-led Patanjali Ayurved. Total income rose to Rs 23,858.50 crore in the first nine months of this fiscal year from Rs 17,608.18 crore in the previous year. Patanjali Foods Ltd (formerly known as Ruchi Soya Industries Ltd), has 25 manufacturing facilities, and an allocation of 6.23 lakh hectares of oil palm plantation. Besides edibl

Patanjali Foods plans to build export portfolio of FMCG, health products

Firm to focus on new launches with high margins and high growth

Patanjali group eyes Rs 1 trillion turnover over the next 5-7 years

Patanjali also plans to carry out oil palm plantations on over 1.5 mn acres in 55 districts of 11 states, and aims to earn annual returns of Rs 2,000 crore in five to seven years

After Patanjali, Reliance Retail could be the next big disruptor in FMCG

Other FMCG companies will have to increase their advertising spends in segments Reliance makes a meaningful acquisition in order to stay competitive.

Ruchi Soya Industries renamed Patanjali Foods with effect from June 24

In May, Ruchi Soya announced the acquisition of Patanjali Ayurved's entire food business for Rs 690 crore, in order to speed up its transition into an FMCG company

Ruchi Soya acquires Patanjali Ayurved's food business for Rs 690 crore

To pay 1% of turnover of products as annual royalty under transfer agreement

Ruchi Soya hits upper circuit on buyout of Patanjali's food retail business

The board also approved to change company's name from Ruchi Soya Industries to Patanjali Foods.

Ruchi Soya to change the name of the company to Patanjali Foods

The board of Ruchi Soya also accorded its in-principle approval for evaluating the most efficient mode of enhancing synergies with Patanjali Ayurved Ltd's food portfolio on an arm's-length basis

Ruchi Soya to launch FPO on March 24; looking to raise Rs 4,300 cr

Edible oil firm Ruchi Soya, which is owned by Baba Ramdev-led Patanjali Ayurved, will hit the capital market with its follow-on public offer (FPO) on March 24 to raise up to Rs 4,300 cr.

Ruchi Soya buys biscuits, noodles unit from Patanjali for Rs 65 cr

Ruchi Soya to use FPO fund to repay debt

Ramdev has no ill-will against modern science, its practitioners: Patanjali

Patanjali Yogpeeth Trust denied allegations by the Indian Medical Association (IMA) that yoga guru Ramdev has misled people by making "unlearned" statements modern medicine

Patanjali Ayurved raises Rs 175 cr through non-convertible debentures

Baba Ramdev-led Patanjali Ayurved on Tuesday said it has raised Rs 175 crore by issuing non-convertible debentures (NCDs).

Patanjali refutes IMA's claims; releases research papers on Coronil

To support its argument, Patanjali has released a bunch of scientific papers on its research for a Covid-19 medicine that was published in popular peer-reviewed journals

Coronil has got Ayush Ministry certification as per WHO scheme: Patanjali

The firm said its Coronil tablet has received certification from the Ayush Ministry as a medicine supporting COVID-19 treatment as per the World Health Organization's certification scheme